Successsful Voriconazole Treatment of Disseminated Fusarium Infection in an Immunocompromised Patient

Fusarium infection is known to cause major morbidity and mortality in immunocompromised hosts. We report the successful treatment of disseminated Fusarium infection with skin manifestations in a severely neutropenic, immunocompromised host with voriconazole, a new second-generation triazole. Voricon...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2003-07, Vol.37 (2), p.311-313
Main Authors: Consigny, Sophie, Dhedin, Nathalie, Datry, Annick, Choquet, Sylvain, Leblond, Véronique, Chosidow, Olivier
Format: Article
Language:English
Subjects:
Aged
Amphotericin B - therapeutic use
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antifungal agents
Antifungal Agents - therapeutic use
Biological and medical sciences
Fusarium - drug effects
Humans
Immunocompromised Host
Male
Medical sciences
Mycoses - drug therapy
Mycoses - physiopathology
Mycoses - transmission
Neutropenia - etiology
Pharmacology. Drug treatments
Pyrimidines - therapeutic use
Treatment Outcome
Triazoles - therapeutic use
Voriconazole
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fusarium infection is known to cause major morbidity and mortality in immunocompromised hosts. We report the successful treatment of disseminated Fusarium infection with skin manifestations in a severely neutropenic, immunocompromised host with voriconazole, a new second-generation triazole. Voriconazole might be an alternative therapy for patients with neutropenia who have fusariosis that is refractory or unresponsive to amphotericin B or its liposomal formulation.
ISSN:1058-4838
1537-6591
DOI:10.1086/375842